Agilent Technologies, Inc. (A)

US — Healthcare Sector
Peers: IQV  MTD  ALC  RMD  HLN  CAH  BDX  WAT  INSM  EW 

Automate Your Wheel Strategy on A

With Tiblio's Option Bot, you can configure your own wheel strategy including A - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol A
  • Rev/Share 6.576
  • Book/Share 23.8198
  • PB 6.4442
  • Debt/Equity 0.4976
  • CurrentRatio 1.9574
  • ROIC 0.0407

 

  • MktCap 43517312935.0
  • FreeCF/Share 5.1802
  • PFCF 29.6844
  • PE 100.0933
  • Debt/Assets 0.2635
  • DivYield 0.0065
  • ROE 0.0687

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation A Rothschild & Co Redburn -- Buy -- $165 Oct. 8, 2025
Upgrade A UBS Neutral Buy -- $170 Oct. 8, 2025
Upgrade A Barclays Underweight Equal Weight $135 $145 Feb. 10, 2025
Initiation A Wells Fargo -- Overweight -- $157 Aug. 28, 2024

News

Agilent lowers annual revenue forecast on soft demand for medical equipment
A
Published: February 26, 2025 by: Reuters
Sentiment: Negative

Medical equipment maker Agilent lowered its annual revenue forecast on Wednesday, as it expects soft demand for its medical tools and equipment from smaller biotech companies.

Read More
image for news Agilent lowers annual revenue forecast on soft demand for medical equipment
Agilent Reports First-Quarter Fiscal Year 2025 Financial Results
A
Published: February 26, 2025 by: Business Wire
Sentiment: Neutral

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.68 billion for the first quarter ended Jan. 31, 2025, representing growth of 1.4% reported and up 1.2% core(1) compared to the first quarter of 2024. First-quarter GAAP net income was $318 million, or $1.11 per share. This compares with $348 million, or $1.18 per share, in the first quarter of fiscal year 2024. Non-GAAP(2) net income was $377 million, or $1.31 per share during the quarter, com.

Read More
image for news Agilent Reports First-Quarter Fiscal Year 2025 Financial Results
Agilent to Report Q1 Earnings: What's in the Cards for the Stock?
A
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Neutral

A's fiscal first-quarter performance is likely to have been influenced by higher expenses, increased CapEx and the Lunar New Year timing shift.

Read More
image for news Agilent to Report Q1 Earnings: What's in the Cards for the Stock?

About Agilent Technologies, Inc. (A)

  • IPO Date 1999-11-18
  • Website https://www.agilent.com
  • Industry Medical - Diagnostics & Research
  • CEO Padraig McDonnell
  • Employees 17900
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.